A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPERA II; ORCHESTRA
  • Sponsors Roche
  • Most Recent Events

    • 12 Jan 2018 According to a Roche media release, based on the data from ORATORIO, OPERA I and OPERA II trial the European Commission (EC) has granted marketing authorisation for OCREVUS (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
    • 10 Nov 2017 According to a Roche media release, final decision regarding approval of OCREVUS from the European Commission is expected in the coming months following which marketing authorisation for OCREVUS will be granted in all 28 member states of the European Union.
    • 10 Nov 2017 According to a Roche media release, based on the data from this and other two studies (700059235 and 700191566), company gained the postitive opinion from the Committee for Medicinal Products for Human Use (CHMP).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top